Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00533442 · ClinicalTrials.gov registry record · Phase 2
Rapamycin Versus Mycophenolate Mofetil in Kidney-Pancreas Recipients
A Phase 2 study, sponsored by University of Miami.
- Completed
- Registry status
- Phase 2
- Development phase
- 170
- Enrollment target
NCT00533442 is a Phase 2 study that has completed, run by University of Miami. The registered enrollment target is 170 participants.
The verdict
NCT00533442, a Phase 2 study, has completed, sponsored by University of Miami.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 170 participants
- Enrollment target
Study Summary
This study was designed to determine which maintenance immunosuppressive agent, rapamycin or mycophenalate mofetil, resulted in better outcome in patients with type 1 diabetes and renal failure, who presented for a kidney-pancreas transplant.
Interventions
- DRUG Mycophenolate Mofetil
- DRUG Tacrolimus
- DRUG Rapamycin
- DRUG Steroids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2000-09 |
| Est. Completion | 2016-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00533442
The ClinicalTrials.gov registry entry for NCT00533442 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Mycophenolate Mofetil is the first listed.
NCT00533442 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00533442 about?
NCT00533442 is a clinical study titled "Rapamycin Versus Mycophenolate Mofetil in Kidney-Pancreas Recipients". This study was designed to determine which maintenance immunosuppressive agent, rapamycin or mycophenalate mofetil, resulted in better outcome in patients with type 1 diabetes and renal failure, who presented for a kidney-pancreas transplant.
What is the current status of trial NCT00533442?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 170 participants. The study started on 2000-09. Estimated completion is 2016-05.
What interventions are being tested in trial NCT00533442?
The interventions under investigation include: Mycophenolate Mofetil (DRUG), Tacrolimus (DRUG), Rapamycin (DRUG), Steroids (DRUG).
Who is sponsoring clinical trial NCT00533442?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.